行情

ADAP

ADAP

Adaptimmune
NASDAQ

实时行情|Nasdaq Last Sale

1.030
+0.010
+0.98%
交易中 15:08 10/15 EDT
开盘
1.040
昨收
1.020
最高
1.090
最低
1.010
成交量
19.16万
成交额
--
52周最高
12.38
52周最低
0.9600
市值
1.08亿
市盈率(TTM)
-1.0851
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADAP 新闻

  • Adaptimmune Is A Good Speculative Biotech, But More Confirmation Is Needed From Next Study
  • Seeking Alpha - Article.5天前
  • Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmunes Cell Therapies
  • GlobeNewswire.6天前
  • Adaptimmune to use Cryoport transport solutions for cell therapies
  • Seeking Alpha - Article.6天前
  • The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
  • Benzinga.6天前

更多

所属板块

生物技术和医学研究
+1.94%
制药与医学研究
+1.27%

热门股票

名称
价格
涨跌幅

ADAP 简况

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
展开

Webull提供Adaptimmune Therapeutics PLC - ADR的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。